ArticlePloS one2020
Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Mathematical Biomarkers of Adaptive Therapy Outcomes in Prostate Cancer.JAMA oncology · 2026Article
- Optimal control theory as a method for designing multidrug adaptive therapy regimens.NPJ systems biology and applications · 2026Article
- Can evolutionary therapy be applied in non-small cell lung cancer?Scientific reports · 2026Article
- Migrastatic therapy as a potential game-changer in adaptive cancer treatment.Scientific reports · 2026Article
- Article
- Cancer, collapse, and the politics of somatic evolution.Evolution, medicine, and public health · 2026Review
- Cancer model with moving extinction threshold reproduces real cancer data.Journal of the Royal Society, Interface · 2025Article
- The balance between intrinsic and ecological fitness reveals hidden regimes in eco-evolutionary population dynamics.Research square · 2025Article
- The balance between intrinsic and ecological fitness reveals hidden regimes in eco-evolutionary population dynamics.bioRxiv : the preprint server for biology · 2025Article
- Adaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence.Clinical Medicine Insights. Oncology · 2025Review
- Stackelberg Evolutionary Games of Cancer Treatment: What Treatment Strategy to Choose if Cancer Can be Stabilized?Dynamic games and applications · 2025Article
- Stability of the Darwinian Dynamics: Effect of Intraspecific Competition and Human Intervention.Dynamic games and applications · 2025Article
- A mathematical framework for comparison of intermittent versus continuous adaptive chemotherapy dosing in cancer.NPJ systems biology and applications · 2024Article
- Threshold-awareness in adaptive cancer therapy.PLoS computational biology · 2024Article
- A war on many fronts: cross disciplinary approaches for novel cancer treatment strategies.Frontiers in genetics · 2024Review
- The effect of tumor composition on the success of adaptive therapy: The case of metastatic Castrate-Resistant Prostate Cancer.PloS one · 2024Article
- A new perspective on tumor progression: Evolution via selection for function.Evolution, medicine, and public health · 2024Article
- Synthetic living materials in cancer biology.Nature reviews bioengineering · 2023Article
- Evolutionary Dynamics and Intermittent Therapy for Metastatic Cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Effective dose window for containing tumor burden under tolerable level.NPJ systems biology and applications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In the absence of curative therapies, treatment of metastatic castrate-resistant prostate cancer (mCRPC) using currently available drugs can be improved by integrating evolutionary principles that govern proliferation of resistant subpopulations into current treatment protocols. Here we develop what is coined as an 'evolutionary stable therapy', within the context of the mathematical model that has been used to inform the first adaptive therapy clinical trial of mCRPC. The objective of this therapy is to maintain a stable polymorphic tumor heterogeneity of sensitive and resistant cells to therapy in order to prolong treatment efficacy and progression free survival. Optimal control analysis shows that an increasing dose titration protocol, a very common clinical dosing process, can achieve tumor stabilization for a wide range of potential initial tumor compositions and volumes. Furthermore, larger tumor volumes may counter intuitively be more likely to be stabilized if sensitive cells dominate the tumor composition at time of initial treatment, suggesting a delay of initial treatment could prove beneficial. While it remains uncertain if metastatic disease in humans has the properties that allow it to be truly stabilized, the benefits of a dose titration protocol warrant additional pre-clinical and clinical investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.